

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Erik Buntinx
Serial No. : 10/752,423
Filed : January 6, 2004
For : METHOD OF TREATING MENTAL DISORDERS USING D4
AND 5-HT2A ANTAGONISTS, INVERSE AGONISTS OR
PARTIAL AGONISTS
Art Unit : 1627
Examiner : Umamaheswari Ramachandran
Customer No. : 1912
Confirmation No.: 3783

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This Supplemental Information Disclosure Statement (SIDS) is being filed to supplement the Information Disclosure Statements filed on September 21, 2010 in connection with the subject application.

In accordance with the duty of disclosure under 37 C.F.R. §1.56, applicants would like to direct the Examiner's attention to the references that are listed on the attached form PTO/SB/08A (4 pages). Copies of the non-patent literature documents are attached hereto.

EFS
Applicant : Erik Buntinx
Serial No. : 10/752,423
Filed : January 6, 2004
Page 2 of 2

Applicant is submitting the subject Supplemental Information Disclosure Statement pursuant to 37 C.F.R. §1.97(b)(4) before the mailing of a first Office Action after the filing of a Request for Continued Examination under 37 C.F.R. §1.114. Accordingly, no fee is deemed necessary in connection with the filing of this Supplemental Information Disclosure Statement. However, if any fee is required in connection with this submission or to maintain the pendency of the subject application, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 01-1785.

Respectfully submitted,

AMSTER, ROTHSTEIN & EBENSTEIN LLP
Attorneys for Applicant
90 Park Avenue
New York, New York 10016
(212) 336-8000

Dated: September 24, 2010
New York, New York

By: /Alan D. Miller/
Alan D. Miller
Registration No. 42,889